Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.

Tristan TownsendVioleta RazanskaiteSusanna DoddDaniel StoreyStephanie MichailJames MorganMichael DaviesDouglas PenmanChristopher WattersMira SwaminathanJoseph SabineAdam ChapmanPhilip J SmithPaul K FlanaganIan ReillyKeith Bodger Sreedhar Subramanian

Published in: Alimentary pharmacology & therapeutics (2020)

Ustekinumab appeared more effective in treating anti-TNF-refractory Crohn's disease and more patients persisted with therapy.

Keyphrases

end stage renal disease
rheumatoid arthritis
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
mesenchymal stem cells